Pain medicine

Postoperative Opioid Prescribing and New Persistent Opioid Use: The Risk of Excessive Prescribing

Ann SurgPublished Retrospective cohort study

Main finding · New persistent opioid useResult — go to the resultAdjusted odds ratio 0.88 95% CI 0.71–1.09

Authors' conclusion

In a cohort of opioid-naïve patients undergoing common surgical procedures, the risk of new persistent opioid use increased with the size of the prescription.

Study context

Population
Opioid-naïve adults undergoing surgery in Michigan, 1/1/2017 to 10/31/2019
Participants
37,654 adults
Exposure
Prescribed opioid vs No opioid
  • Prescribed opioidn = 31,920
Outcome
New persistent opioid use (≥1 opioid fill post-discharge days 4–90 and ≥1 fill days 91–180)
Methodological detailsstatewide clinical registry, prescription drug monitoring program
  • Statewide clinical registry
  • Prescription drug monitoring program

Main finding

New persistent opioid use

Adjusted odds ratio

0.88

95% CI 0.71–1.09

Prescribed opioid vs No opioid
aOR 0.88 (95% CI 0.71–1.09)

As reported in the abstract

Patients developing new persistent opioid use, overall
622 (1.7%)

Observational data: associations, not effects.

Further findings

OutcomeSmallest quartileSecond largest quartileLargest quartileaOR (95% CI)
New persistent opioid use by prescription size quartile (among patients prescribed an opioid)Second largest quartile vs Smallest quartile · reference: smallest quartile7 (IQR 1) pills12 (IQR 3) pills20 (IQR 7) pills1.39 (1.04–1.86)
OutcomeaOR
New persistent opioid use by prescription size quartile (among patients prescribed an opioid)Largest quartile vs Smallest quartile · CI garbled in the abstract · reference: smallest quartile1.97

Original publication

Postoperative Opioid Prescribing and New Persistent Opioid Use: The Risk of Excessive Prescribing. Ann Surg. Published 21 January 2022. doi:10.1097/sla.0000000000005392

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.